Novartis boss says pharma R&D investment in India “will cease”

In an interview with BBC India Business Report, the head of Novartis in India, Ranjit Shahani, suggested that pharma R&D investment in India will cease following the Supreme Court decision not to grant the Swiss pharma company a patent for its oncology drug Glivec. He explained that Novartis was “disappointed” by the court’s decision, and stressed that 95% of Indian patients prescribed Glivec receive it free of charge.

In the context of the interview, it is not clear whether Mr Shahani’s comments are a formal statement of Novartis’ intent to stop all R&D in India immediately (there is no mention of this on the Novartis website), or a more general “sea change” in industry sentiment towards the country, with several big pharma companies losing out recent court cases around intellectual property.

Click here to watch the full interview on the BBC website.